Five patients with T cell lymphoma including adult T-cell leukemia-lymphoma were treated with a combination chemotherapy regimen consisting of cyclophosphamide, vincristine, doxorubicin and dacarbazine (CYVADIC). Three patients acheived complete remission and one partial remission. Toxity of CYVADIC therapy includes moderate to severe nausea and vomiting. These results suggest that CYVADIC is an effective combination chemotherapy regimen for the treatment of T-cell lymphoma. However, more trials are required for the definite evaluation of the effects of CYVADIC therapy.
